Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer

NEXT STORY
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2018
PREV STORY
Nucleic Acid Testing Market Will Hit At A CAGR Of 7.5% From 2017 To 2027
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

author_avatar
NASDAQ Market News

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)

First treatment with a tumor-agnostic indication at the time of initial FDA approval75% overall ...

author_avatar
NASDAQ Market News

Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update

author_avatar
NASDAQ Market News